Boston Children’s Hospital, Dana-Farber Cancer Institute, and Broad Clinical Labs have launched BrightSeq, a collaborative initiative aimed at enhancing pediatric cancer genomic profiling through combined tissue and liquid biopsy sequencing. The consortium focuses on improving prognostic assessments and enabling precision medicine in rare pediatric malignancies. Concurrently, advances in co-culture platforms replicating leukemia microenvironments and novel pediatric cancer genomics initiatives underscore a growing emphasis on integrated, precise diagnostic approaches in pediatric oncology.